JP2020506970A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020506970A5 JP2020506970A5 JP2019563699A JP2019563699A JP2020506970A5 JP 2020506970 A5 JP2020506970 A5 JP 2020506970A5 JP 2019563699 A JP2019563699 A JP 2019563699A JP 2019563699 A JP2019563699 A JP 2019563699A JP 2020506970 A5 JP2020506970 A5 JP 2020506970A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- cancer
- groups
- substituted
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 36
- -1 R a1 Chemical group 0.000 claims 29
- 125000000217 alkyl group Chemical group 0.000 claims 22
- 125000005843 halogen group Chemical group 0.000 claims 18
- 206010028980 Neoplasm Diseases 0.000 claims 16
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 14
- 201000011510 cancer Diseases 0.000 claims 11
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 9
- 125000000304 alkynyl group Chemical group 0.000 claims 9
- 125000001153 fluoro group Chemical group F* 0.000 claims 9
- 125000001072 heteroaryl group Chemical group 0.000 claims 8
- 125000000623 heterocyclic group Chemical group 0.000 claims 8
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 7
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 7
- 239000002253 acid Substances 0.000 claims 6
- 239000002904 solvent Substances 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 5
- 238000006243 chemical reaction Methods 0.000 claims 5
- 125000005842 heteroatom Chemical group 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 201000005262 Chondroma Diseases 0.000 claims 3
- 208000005243 Chondrosarcoma Diseases 0.000 claims 3
- 206010039491 Sarcoma Diseases 0.000 claims 3
- 239000002671 adjuvant Substances 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000003085 diluting agent Substances 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 201000008808 Fibrosarcoma Diseases 0.000 claims 2
- 206010024612 Lipoma Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 206010046431 Urethral cancer Diseases 0.000 claims 2
- 206010046458 Urethral neoplasms Diseases 0.000 claims 2
- 229910001413 alkali metal ion Inorganic materials 0.000 claims 2
- 206010016629 fibroma Diseases 0.000 claims 2
- 201000011066 hemangioma Diseases 0.000 claims 2
- 230000002489 hematologic effect Effects 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 229910001507 metal halide Inorganic materials 0.000 claims 2
- 150000005309 metal halides Chemical class 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000003444 phase transfer catalyst Substances 0.000 claims 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 201000003076 Angiosarcoma Diseases 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000000471 Dysplastic Nevus Syndrome Diseases 0.000 claims 1
- 206010062805 Dysplastic naevus Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 201000001342 Fallopian tube cancer Diseases 0.000 claims 1
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims 1
- 208000007569 Giant Cell Tumors Diseases 0.000 claims 1
- 208000002927 Hamartoma Diseases 0.000 claims 1
- 208000001258 Hemangiosarcoma Diseases 0.000 claims 1
- 206010019629 Hepatic adenoma Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000002260 Keloid Diseases 0.000 claims 1
- 206010023330 Keloid scar Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 239000002841 Lewis acid Substances 0.000 claims 1
- 208000002404 Liver Cell Adenoma Diseases 0.000 claims 1
- 206010027145 Melanocytic naevus Diseases 0.000 claims 1
- 208000015021 Meningeal Neoplasms Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000009905 Neurofibromatoses Diseases 0.000 claims 1
- 208000007256 Nevus Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 208000000035 Osteochondroma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000005678 Rhabdomyoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000032383 Soft tissue cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 206010043276 Teratoma Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 206010047741 Vulval cancer Diseases 0.000 claims 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 1
- 230000001919 adrenal effect Effects 0.000 claims 1
- 150000001345 alkine derivatives Chemical class 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 201000006491 bone marrow cancer Diseases 0.000 claims 1
- 201000002143 bronchus adenoma Diseases 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000013066 combination product Substances 0.000 claims 1
- 229940127555 combination product Drugs 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 1
- 210000002249 digestive system Anatomy 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 claims 1
- 201000010255 female reproductive organ cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000006359 hepatoblastoma Diseases 0.000 claims 1
- 201000002735 hepatocellular adenoma Diseases 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 210000001117 keloid Anatomy 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 150000007517 lewis acids Chemical class 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000022006 malignant tumor of meninges Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 claims 1
- 208000009091 myxoma Diseases 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 201000004931 neurofibromatosis Diseases 0.000 claims 1
- 208000004649 neutrophil actin dysfunction Diseases 0.000 claims 1
- 239000007800 oxidant agent Substances 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 201000002314 small intestine cancer Diseases 0.000 claims 1
- 201000011096 spinal cancer Diseases 0.000 claims 1
- 208000014618 spinal cord cancer Diseases 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 229940126585 therapeutic drug Drugs 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 206010046885 vaginal cancer Diseases 0.000 claims 1
- 208000013139 vaginal neoplasm Diseases 0.000 claims 1
- 201000005102 vulva cancer Diseases 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 0 CC1=C(*)C([N+]([O-])=O)=C(C)N(C)C1* Chemical compound CC1=C(*)C([N+]([O-])=O)=C(C)N(C)C1* 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762455641P | 2017-02-07 | 2017-02-07 | |
| US62/455,641 | 2017-02-07 | ||
| US201762594794P | 2017-12-05 | 2017-12-05 | |
| US62/594,794 | 2017-12-05 | ||
| PCT/GB2018/050346 WO2018146472A1 (en) | 2017-02-07 | 2018-02-07 | Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020506970A JP2020506970A (ja) | 2020-03-05 |
| JP2020506970A5 true JP2020506970A5 (enExample) | 2021-03-04 |
| JP7229176B2 JP7229176B2 (ja) | 2023-02-27 |
Family
ID=61274298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019563699A Active JP7229176B2 (ja) | 2017-02-07 | 2018-02-07 | ヒドロカルビルスルホニル置換ピリジンおよび癌の治療におけるそれらの使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11161815B2 (enExample) |
| EP (1) | EP3580203A1 (enExample) |
| JP (1) | JP7229176B2 (enExample) |
| KR (1) | KR20190115014A (enExample) |
| CN (1) | CN110382464A (enExample) |
| AU (1) | AU2018218522B2 (enExample) |
| BR (1) | BR112019016248A2 (enExample) |
| CA (1) | CA3051539A1 (enExample) |
| MA (1) | MA47458A (enExample) |
| MX (1) | MX392900B (enExample) |
| RU (1) | RU2019128063A (enExample) |
| WO (1) | WO2018146472A1 (enExample) |
| ZA (1) | ZA201904966B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201514021D0 (en) | 2015-08-07 | 2015-09-23 | Arner Elias Set Jeno | Novel Pyridines and their use in the treatment of cancer |
| US11208384B2 (en) | 2017-02-07 | 2021-12-28 | Oblique Therapeutics Ab | Sulfinylpyridines and their use in the treatment of cancer |
| EP3580215A1 (en) | 2017-02-07 | 2019-12-18 | Oblique Therapeutics AB | Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer |
| US11161815B2 (en) * | 2017-02-07 | 2021-11-02 | Oblique Therapeutics Ab | Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer |
| BR112019016233A2 (pt) | 2017-02-07 | 2020-04-07 | Oblique Therapeutics Ab | piridinas substituídas com heterociclilsulfonila e uso das mesmas no tratamento de câncer |
| WO2019155086A1 (en) * | 2018-02-12 | 2019-08-15 | Cinda Pharma Ab | Thioredoxin reductase inhibitors for use in the treatment of cancer |
| EP4201929B1 (en) * | 2021-12-24 | 2024-08-14 | geneXplain GmbH | Quinoxaline thioredoxin reductase inhibitors |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0031173B1 (en) | 1979-12-19 | 1983-09-14 | Duphar International Research B.V | New nitrothiophenes, method of preparing the new compounds, as well as fungicidal and/or bactericidal compositions on the basis of the new compounds |
| US4456469A (en) | 1980-03-07 | 1984-06-26 | E. I. Du Pont De Nemours And Company | Pyridyl sulfone herbicides |
| AU543161B2 (en) | 1980-03-07 | 1985-04-04 | E.I. Du Pont De Nemours And Company | Pyrimidine or s.triazine derivatives |
| US4791127A (en) | 1985-10-07 | 1988-12-13 | Nippon Kayaku Kabushiki Kaisha | Alkanesulfonate derivatives and their use as insecticides, acaricides or nematicides |
| JPS63166865A (ja) * | 1986-12-22 | 1988-07-11 | バイエル・アクチエンゲゼルシヤフト | 置換されたフエノキシピリジン類 |
| DE3729071A1 (de) * | 1986-12-22 | 1988-06-30 | Bayer Ag | Substituierte phenoxypyridine |
| DE3812177A1 (de) | 1988-04-13 | 1989-10-26 | Bayer Ag | 2-phenylsulfinyl-nitro-pyridine, verfahren zu ihrer herstellung und ihre verwendung |
| US5945425A (en) | 1994-04-29 | 1999-08-31 | G.D. Searle & Co. | Method of using (H+ /K+)ATPase inhibitors as antiviral agents |
| JP2002515023A (ja) | 1995-08-24 | 2002-05-21 | ビーエーエスエフ アクチェンゲゼルシャフト | Ｎ−複素環化合物、その製造用中間体、それを含む組成物及び有害菌類防除にそれを使用する方法 |
| DE19531148A1 (de) * | 1995-08-24 | 1997-02-27 | Basf Ag | Fungizide Pyridin-2-yl-Derivate |
| DE19531348A1 (de) | 1995-08-25 | 1997-02-27 | Gsf Forschungszentrum Umwelt | Antikörper mit zwei oder mehr Spezifitäten zur selektiven Eliminierung von Zellen in vivo |
| WO1998054139A1 (de) | 1997-05-30 | 1998-12-03 | Basf Aktiengesellschaft | Verfahren zur herstellung substituierter thiopyridine |
| US6284923B1 (en) | 1997-08-22 | 2001-09-04 | Tularik Inc | Substituted benzene compounds as antiproliferative and cholesterol lowering action |
| WO1999018096A1 (en) | 1997-10-02 | 1999-04-15 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| US6297239B1 (en) | 1997-10-08 | 2001-10-02 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| US6191170B1 (en) | 1998-01-13 | 2001-02-20 | Tularik Inc. | Benzenesulfonamides and benzamides as therapeutic agents |
| ES2193607T3 (es) | 1998-01-16 | 2003-11-01 | Hoffmann La Roche | Derivados de benzosulfona . |
| AU2001245353A1 (en) | 2000-02-29 | 2001-09-12 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
| US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| AU2003211427A1 (en) | 2002-02-18 | 2003-09-04 | Ishihara Sangyo Kaisha, Ltd. | Pyridine derivatives or salts thereof and cytokine production inhibitors containing the same |
| US20030236287A1 (en) * | 2002-05-03 | 2003-12-25 | Piotrowski David W. | Positive allosteric modulators of the nicotinic acetylcholine receptor |
| US7037902B2 (en) | 2002-07-03 | 2006-05-02 | Receptron, Inc. | Affinity small molecules for the EPO receptor |
| WO2005007621A2 (en) | 2003-05-30 | 2005-01-27 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase inhibitors |
| MXPA06014129A (es) | 2004-06-04 | 2007-03-07 | Arena Pharm Inc | Derivados de arilo y heteroarilo sustituidos como moduladores del metabolismo y profilaxis y tratamiento de trastornos relacionados con los mismos. |
| US20060019967A1 (en) | 2004-07-21 | 2006-01-26 | Su-Ying Wu | SARS CoV main protease inhibitors |
| GB0426313D0 (en) | 2004-12-01 | 2005-01-05 | Merck Sharp & Dohme | Therapeutic agents |
| WO2006083692A2 (en) | 2005-01-28 | 2006-08-10 | Mount Sinai Schoool Of Medicine | Methods of identifying modulators of bromodomains |
| GB0504828D0 (en) | 2005-03-09 | 2005-04-13 | Merck Sharp & Dohme | Therapeutic agents |
| EP1976495A2 (en) | 2006-01-06 | 2008-10-08 | Aarhus Universitet | Compounds acting on the serotonin transporter |
| JP2009535307A (ja) | 2006-04-28 | 2009-10-01 | アベキサ・リミテッド | インテグラーゼ阻害剤３ |
| US20090005422A1 (en) | 2006-05-22 | 2009-01-01 | Thioredoxin Systems Ab | Bacterial thioredoxin reductase inhibitors and methods for use thereof |
| EP2170830B1 (en) | 2007-07-17 | 2014-10-15 | Plexxikon, Inc. | 2-FLUORO-BENZENESULFONAMIDE COMPOUNDS AS Raf KINASE MODULATORS |
| WO2010007756A1 (ja) * | 2008-07-14 | 2010-01-21 | 塩野義製薬株式会社 | Ｔｔｋ阻害作用を有するピリジン誘導体 |
| CN101723932B (zh) * | 2008-10-31 | 2013-11-20 | 北京以岭生物工程技术有限公司 | 硝基吡啶乙烯亚胺化合物、其药物组合物及其制备方法和用途 |
| AU2010253820A1 (en) | 2009-05-28 | 2011-12-22 | President And Fellows Of Harvard College | N,N-diarylurea compounds and N,N'-diarylthiourea compounds as inhibitors of translation initiation |
| US9567318B2 (en) | 2009-08-17 | 2017-02-14 | Memorial Sloan-Kettering Cancer Center | Substituted pyrimidine compounds and uses thereof |
| US9206125B2 (en) | 2010-02-10 | 2015-12-08 | Public University Corporation Yokohama City University | Use of compound binding to mSin3B that specifically binds to neuron restrictive silencer factor (NRSF) |
| CN102206172B (zh) | 2010-03-30 | 2015-02-25 | 中国医学科学院医药生物技术研究所 | 一组取代双芳基化合物及其制备方法和抗病毒应用 |
| EP2609089A1 (en) | 2010-08-27 | 2013-07-03 | Universität des Saarlandes | Selective 17beta-hydroxysteroid dehydrogenase type 1 inhibitors |
| WO2013119931A1 (en) | 2012-02-10 | 2013-08-15 | The Board Of Regents Of The University Of Texas System | Modulators of exchange proteins directly activated by camp (epacs) |
| JP6393322B2 (ja) | 2013-07-10 | 2018-09-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規なキラル窒素−リン配位子及びアルケン類の不斉水素化のためのその使用 |
| CN104672214B (zh) | 2013-12-03 | 2019-04-12 | 上海翰森生物医药科技有限公司 | 具有alk抑制活性的化合物及其制备与用途 |
| CN105503827B (zh) | 2014-10-11 | 2019-09-24 | 上海翰森生物医药科技有限公司 | Egfr抑制剂及其制备方法和用途 |
| CN104672241B (zh) | 2015-01-29 | 2018-04-24 | 王磊 | 吡咯并[2,3-d]嘧啶类化合物及其用途 |
| CN105085483B (zh) | 2015-06-04 | 2019-01-01 | 湖北生物医药产业技术研究院有限公司 | 激酶抑制剂及其应用 |
| CN104987324B (zh) | 2015-06-04 | 2018-05-04 | 湖北生物医药产业技术研究院有限公司 | 作为alk抑制剂的嘧啶衍生物 |
| GB201514021D0 (en) | 2015-08-07 | 2015-09-23 | Arner Elias Set Jeno | Novel Pyridines and their use in the treatment of cancer |
| EP3580215A1 (en) | 2017-02-07 | 2019-12-18 | Oblique Therapeutics AB | Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer |
| US11208384B2 (en) | 2017-02-07 | 2021-12-28 | Oblique Therapeutics Ab | Sulfinylpyridines and their use in the treatment of cancer |
| US11161815B2 (en) * | 2017-02-07 | 2021-11-02 | Oblique Therapeutics Ab | Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer |
| BR112019016233A2 (pt) | 2017-02-07 | 2020-04-07 | Oblique Therapeutics Ab | piridinas substituídas com heterociclilsulfonila e uso das mesmas no tratamento de câncer |
-
2018
- 2018-02-07 US US16/484,057 patent/US11161815B2/en not_active Expired - Fee Related
- 2018-02-07 EP EP18707131.1A patent/EP3580203A1/en not_active Withdrawn
- 2018-02-07 CN CN201880010169.1A patent/CN110382464A/zh active Pending
- 2018-02-07 JP JP2019563699A patent/JP7229176B2/ja active Active
- 2018-02-07 MX MX2019009266A patent/MX392900B/es unknown
- 2018-02-07 KR KR1020197024697A patent/KR20190115014A/ko not_active Ceased
- 2018-02-07 BR BR112019016248A patent/BR112019016248A2/pt not_active IP Right Cessation
- 2018-02-07 MA MA047458A patent/MA47458A/fr unknown
- 2018-02-07 RU RU2019128063A patent/RU2019128063A/ru unknown
- 2018-02-07 CA CA3051539A patent/CA3051539A1/en active Pending
- 2018-02-07 AU AU2018218522A patent/AU2018218522B2/en not_active Ceased
- 2018-02-07 WO PCT/GB2018/050346 patent/WO2018146472A1/en not_active Ceased
-
2019
- 2019-07-29 ZA ZA2019/04966A patent/ZA201904966B/en unknown
-
2021
- 2021-10-29 US US17/514,288 patent/US20220119348A1/en not_active Abandoned